Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3693532 | 0.91 | HSD11B1 (0.38) | MGLLHSD11B1 | |
| SCHEMBL3690688 | 0.89 | SCD5 (0.42) | — | |
| SCHEMBL3688380 | 0.89 | TRPV1 (0.43) | MGLLKMT2AMEN1 | |
| SCHEMBL3794245 | 0.88 | SPR (0.41) | MGLL | |
| SCHEMBL3686406 | 0.88 | RBP4 (0.45) | — | |
| SCHEMBL3793710 | 0.87 | KDM1A (0.38) | MGLLHSD11B1 | |
| SCHEMBL3692964 | 0.87 | SCD5 (0.48) | — | |
| SCHEMBL3691242 | 0.87 | SCD5 (0.48) | — | |
| SCHEMBL3691240 | 0.87 | SCD5 (0.48) | — | |
| SCHEMBL3688700 | 0.87 | HTR1A (0.45) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | claimed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | MGLL 2649/4885HSD11B1 2958/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.